π Share this article The United States and United Kingdom Strike Zero-Tariff Agreement on Medicines. Representative image of medicine trade. The UK and US have reached a landmark commercial pact that will ensure zero levies on British medicine products going into the American market. The Terms of the Pact In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will stay at nothing for a period of the next three years. This deal is in response to earlier warnings to significantly raise tariffs on patented drug products, with figures discussed as high as one hundred percent. "This agreement between the Britain strengthens the global environment for innovative medicines and brings long-overdue balance to American-British pharmaceutical trade," a statement said. Trade Impact Drugs represent one of the Britain's biggest goods shipped to the America, which is by far the primary market for large UK drugmakers. Statistics indicate that in the 12 months leading up to last September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that period. "This guarantee secures work, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated. Specific UK Commitments The deal involves several notable pledges from the UK: Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent. Higher Drug Budget: There is a target to double total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years. Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments were more than twenty percent. Broader Context The pact follows a ongoing row between the drug companies and the UK government over spending levels and regulatory access. This friction were intensified by claims that American consumers were charged a premium for the same drugs than consumers in the other developed nations. In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward American operations. The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
Representative image of medicine trade. The UK and US have reached a landmark commercial pact that will ensure zero levies on British medicine products going into the American market. The Terms of the Pact In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will stay at nothing for a period of the next three years. This deal is in response to earlier warnings to significantly raise tariffs on patented drug products, with figures discussed as high as one hundred percent. "This agreement between the Britain strengthens the global environment for innovative medicines and brings long-overdue balance to American-British pharmaceutical trade," a statement said. Trade Impact Drugs represent one of the Britain's biggest goods shipped to the America, which is by far the primary market for large UK drugmakers. Statistics indicate that in the 12 months leading up to last September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that period. "This guarantee secures work, stimulates funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated. Specific UK Commitments The deal involves several notable pledges from the UK: Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent. Higher Drug Budget: There is a target to double total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years. Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments were more than twenty percent. Broader Context The pact follows a ongoing row between the drug companies and the UK government over spending levels and regulatory access. This friction were intensified by claims that American consumers were charged a premium for the same drugs than consumers in the other developed nations. In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward American operations. The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.